Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT02331602

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02331602
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02331602. Randomized; no masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2015-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
Acronym
RIVAL-AF
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Dabigatran
Lead sponsor
Yokohama City University Medical Center (class: other)
Collaborator
Yokohama City University (class: other)

Record details

Record id
cardio:ct-nct02331602
Content hash
6911c9384a4faaa45251ecac541f68bcec34fe708fa13eb87d9d09060dc96e27